Patents by Inventor Tomohiro Ohashi
Tomohiro Ohashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240309016Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: March 15, 2024Publication date: September 19, 2024Inventors: Mitsunori KONO, Yusuke SASAKI, Yuya OGURO, Zenichi IKEDA, Osamu KUBO, Masaki SETO, Toru YAMASHITA, Makoto KAMATA, Kenjiro SATO, Matthew Thomas REYNOLDS, Kazuaki TAKAMI, Asato KINA, Takafumi YUKAWA, Minoru NAKAMURA, Taku KAMEI, Hiroyuki KAKEI, Fumie YAMAGUCHI, Tomohiro OHASHI, Keiko KAKEGAWA, Takuto KOJIMA, Florian PÜNNER, Masataka MURAKAMI, Takahiko TANIGUCHI, Tatsuki KOIKE, Yuichi KAJITA, Yuhei MIYANOHANA, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Yasushi HATTORI, Eiji KIMURA, Martin Alexander PAWLICZEK, Marilena PIRA, Shuhei IKEDA, Noriyuki TEZUKA, Yoshikazu WATANABE, Kevin CURRAN, Nicolle DOERING, Maria HOPKINS, Ben JOHNSON, Andre KIRYANOV, Jon LAM, Sean MURPHY, Natasha O'ROURKE, Holly REICHARD, Paul TANIS, Yunlong ZHANG
-
Patent number: 12072627Abstract: A resist composition containing: (A) a resin containing a repeating unit having an acid-labile group; (B) a photo-acid generator shown by a general formula (B-1); and (C) a solvent, where W1 represents a cyclic divalent hydrocarbon group having 4 to 12 carbon atoms and containing a heteroatom; W2 represents a cyclic monovalent hydrocarbon group having 4 to 14 carbon atoms and not containing a heteroatom; Rf represents a divalent organic group shown by the following general formula; and M+ represents an onium cation. This provides a resist composition and a patterning process that uses the resist composition that show a particularly favorable mask dimension dependency (mask error factor: MEF), LWR, and critical dimension uniformity (CDU) particularly in photolithography where a high-energy beam such as an ArF excimer laser beam is used as a light source.Type: GrantFiled: May 15, 2023Date of Patent: August 27, 2024Assignee: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Teppei Adachi, Shinya Yamashita, Masaki Ohashi, Tomohiro Kobayashi, Kenichi Oikawa, Takayuki Fujiwara
-
Patent number: 12050402Abstract: A resist composition containing: (A) a resin containing a repeating unit having an acid-labile group and further containing at least one repeating unit having an aromatic substituent; (B) a photo-acid generator shown by a general formula (B-1); and (C) a solvent, where W1 represents a cyclic divalent hydrocarbon group having 4 to 12 carbon atoms with a heteroatom; W2 represents a cyclic monovalent hydrocarbon group having 4 to 14 carbon atoms without a heteroatom; Rf represents a divalent organic group shown by the following general formula; and M+ represents an onium cation. This provides a resist composition and a patterning process of using it that show a particularly favorable mask dimension dependency and CDU in photolithography where a light source is a high-energy beam such as a KrF excimer laser beam, an electron beam, or an extreme ultraviolet ray.Type: GrantFiled: January 21, 2021Date of Patent: July 30, 2024Assignee: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Teppei Adachi, Tomohiro Kobayashi, Kenichi Oikawa, Masaki Ohashi, Takayuki Fujiwara
-
Publication number: 20240217957Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: November 29, 2023Publication date: July 4, 2024Inventors: Asato KINA, Zenichi IKEDA, Mitsunori KONO, Yuya OGURO, Osamu KUBO, Toru YAMASHITA, Kazuaki TAKAMI, Takafumi YUKAWA, Masaki SETO, Makoto KAMATA, Kenjiro SATO, Masataka MURAKAMI, Yusuke SASAKI, Matthew Thomas REYNOLDS, Minoru NAKAMURA, Taku KAMEI, Hiroyuki KAKEI, Fumie YAMAGUCHI, Tomohiro OHASHI, Takuto KOJIMA, Keiko KAKEGAWA, Florian PÜNNER, Shinji NAKAMURA, Nao MORISHITA, Tadashi HIDAKA, Sachie TAKASHIMA, Takahiko TANIGUCHI
-
Publication number: 20230037538Abstract: The present invention relates to compounds expected to be useful in the prevention and/or treatment of diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, chronic traumatic encephalopathy, Alzheimer's disease, frontotemporal lobar degeneration, multisystem proteinopathy and the like, a method for preventing or treating such diseases, and the like.Type: ApplicationFiled: June 23, 2022Publication date: February 9, 2023Inventors: Dennis Solas, Anatoliy Kitaygorodskyy, Kumar Paulvannan, Vishwanath R. Lingappa, Masato Yoshikawa, Masahiro Ito, Yuta Tanaka, Keiko Kakegawa, Tomohiro Ohashi, Takuto Kojima, Akinori Toita, Osamu Kubo, Fumiaki Kikuchi, Florian Pünner, Junsi Wang
-
Patent number: 11459325Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: January 30, 2019Date of Patent: October 4, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuta Tanaka, Tomohiro Ohashi, Zenichi Ikeda, Yuta Tanaka, Florian Pünner, Takeshi Yamamoto, Keiko Kakegawa, Fumiaki Kikuchi, Nao Morishita, Takahito Kasahara, Masaki Seto, Minoru Nakamura, Kazuaki Takami, Masataka Murakami, Masaki Daini, Satoshi Mikami, Minoru Sasaki
-
Publication number: 20220289679Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: July 28, 2020Publication date: September 15, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Yuta TANAKA, Keiko KAKEGAWA, Takahito KASAHARA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Tomohiro OHASHI, Zenichi IKEDA, Florian PUENNER, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
-
Publication number: 20220274982Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: July 28, 2020Publication date: September 1, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Yuta TANAKA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Yasufumi WADA, Keiko KAKEGAWA, Takahito KASAHARA, Tomohiro OHASHI, Junsi WANG, Zenichi IKEDA, Florian PUENNER, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
-
Patent number: 11236099Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: June 19, 2018Date of Patent: February 1, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
-
Publication number: 20220017530Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: September 15, 2021Publication date: January 20, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
-
Publication number: 20210139491Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: June 19, 2018Publication date: May 13, 2021Inventors: Kazuaki TAKAMI, Masaki SETO, Shinobu SASAKI, Haruhi ANDO, Masaki OGINO, Tomoko OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Yasuhiro TSUKIMI, Masami YAMADA, Kenichiro SHIMOKAWA, Takeshi WAKABAYASHI, Masataka MURAKAMI, Makoto FUSHIMI, Tomohiro OKAWA, Jinichi YONEMORI, Tomohiro OHASHI, Hideo SUZUKI, Hironobu MAEZAKI, Ayumu SATO, Yasutomi ASANO, Steve SWANN
-
Publication number: 20210087186Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: January 30, 2019Publication date: March 25, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Tomohiro OHASHI, Zenichi IKEDA, Yuta TANAKA, Florian PÜNNER, Takeshi YAMAMOTO, Keiko KAKEGAWA, Fumiaki KIKUCHI, Nao MORISHITA, Takahito KASAHARA, Masaki SETO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Satoshi MIKAMI, Minoru SASAKI
-
Patent number: 10548877Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.Type: GrantFiled: March 9, 2017Date of Patent: February 4, 2020Assignee: Takeda Pharmaceutical Company LimitedInventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Kouji Fuji, Tomohiro Ohashi, Makoto Fushimi, Kei Masuda, Tatsuki Koike, Takeshi Wakabayashi, Jinichi Yonemori, Masami Yamada
-
Publication number: 20190083467Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.Type: ApplicationFiled: March 9, 2017Publication date: March 21, 2019Inventors: Masaki OGINO, Eiji KIMURA, Shinkichi SUZUKI, Kouji FUJI, Tomohiro OHASHI, Makoto FUSHIMI, Kei MASUDA, Tatsuki KOIKE, Takeshi WAKABAYASHI, Jinichi YONEMORI, Masami YAMADA
-
Patent number: 10131653Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: April 22, 2016Date of Patent: November 20, 2018Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taku Kamei, Yasuyoshi Arikawa, Tomohiro Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Takashi Miki, Jinichi Yonemori, Yuya Oguro, Takahiro Sugimoto, Masaki Seto, Goushi Nishida, Makoto Kamata, Hiroshi Imoto
-
Publication number: 20180155333Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: April 22, 2016Publication date: June 7, 2018Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taku KAMEI, Yasuyoshi ARIKAWA, Tomohiro OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Takashi MIKI, Jinichi YONEMORI, Yuya OGURO, Takahiro SUGIMOTO, Masaki SETO, Goushi NISHIDA, Makoto KAMATA, Hiroshi IMOTO
-
Patent number: 9263313Abstract: A plasma processing apparatus is provided which includes a processing chamber disposed in a vacuum container, in a decompressed inside of which plasma is formed, a sample stage disposed in a lower part of the processing chamber, on a top surface of which a sample is mounted, a dielectric film made of a dielectric that forms a mounting surface on which the sample is mounted, and electrodes arranged inside the dielectric film and supplied with power for chucking and holding the sample onto the dielectric film, and when the sample is mounted on the sample stage, the sample is kept mounted on the sample stage until a sample temperature becomes a predetermined temperature or until a predetermined time elapses, and power is then supplied to the electrodes to chuck the sample to the sample stage and then start processing on the sample using the plasma.Type: GrantFiled: February 19, 2014Date of Patent: February 16, 2016Assignee: Hitachi High-Technologies CorporationInventors: Kohei Sato, Yuya Mizobe, Tomohiro Ohashi
-
Patent number: 8897906Abstract: A vacuum processing apparatus includes a robot connected to a vacuum container to carry a wafer on one of its two arms to or from a processing chamber; a unit to detect an amount of deviation of the wafer from a predetermined wafer mounting position on the arm that may occur when the robot carries the wafer into or out of the processing chamber; and an adjusting device to adjust the operation of the robot based on the detected amount of deviation. The adjusting device adjusts the robot operation based on the result of a teaching operation performed in advance. After being subjected to the initial teaching operation, the robot again undergoes a second teaching operation according to the information on the amount of wafer position deviation that is detected by moving the wafer in a predetermined transfer pattern, before the wafer processing is performed.Type: GrantFiled: September 20, 2011Date of Patent: November 25, 2014Assignee: Hitachi High-Technologies CorporationInventors: Tomohiro Ohashi, Akitaka Makino, Hiroho Kitada, Hideki Kihara
-
Publication number: 20140295671Abstract: A plasma processing apparatus is provided which includes a processing chamber disposed in a vacuum container, in a decompressed inside of which plasma is formed, a sample stage disposed in a lower part of the processing chamber, on a top surface of which a sample is mounted, a dielectric film made of a dielectric that forms a mounting surface on which the sample is mounted, and electrodes arranged inside the dielectric film and supplied with power for chucking and holding the sample onto the dielectric film, and when the sample is mounted on the sample stage, the sample is kept mounted on the sample stage until a sample temperature becomes a predetermined temperature or until a predetermined time elapses, and power is then supplied to the electrodes to chuck the sample to the sample stage and then start processing on the sample using the plasma.Type: ApplicationFiled: February 19, 2014Publication date: October 2, 2014Inventors: Kohei Sato, Yuya Mizobe, Tomohiro Ohashi
-
Patent number: 8569177Abstract: A plasma processing apparatus is provided which includes an inert gas supply route connected to a process gas supply piping which supplies a process gas into a processing chamber in a vacuum vessel, a valve which opens or closes the inert gas supply route, and an adjuster which adjusts a flow rate of the inert gas. When processing of a sample is complete, an inert gas is supplied into the process gas supply piping so that a pressure in the process gas supply piping is maintained at a pressure higher than a pressure at which a compound of the process gas and a material of an inner wall of the process gas supply piping vaporizes.Type: GrantFiled: August 9, 2012Date of Patent: October 29, 2013Assignee: Hitachi High-Technologies CorporationInventors: Tomohiro Ohashi, Akitaka Makino, Hiroho Kitada, Muneo Furuse, Tomoyuki Tamura
